SEC Form 4 · accession 0001209191-18-041879
G1 Therapeutics, Inc. · GTHX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Demaree
Officer — Chief Commercial Officer
Period of report
Jul 3, 2018
Accepted (ET)
Jul 6, 2018 · 4:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001560241
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $45.50 | Jul 3, 2018 | A | 225,000 | A | — | Jul 3, 2028 | Common Stock | 225,000 | 225,000 | D |
Explanation of responses
- F1The shares underlying this option vest as to 25% of the shares on July 3, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.